Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals Assigned Patent

12/31/2013 | 03:06am US/Eastern
Recommend:
0

By Targeted News Service

ALEXANDRIA, Va., Dec. 31 -- Regeneron Pharmaceuticals, Tarrytown, N.Y., has been assigned a patent (8,613,927) developed by five co-inventors for a "high affinity human antibodies to human nerve growth factor." The co-inventors are Lynn MacDonald, White Plains, N.Y., Richard Torres, New York, Marc R. Morra, Beacon Falls, Conn., Joel H. Martin, Putnam Valley, N.Y., and Joel C. Reinhardt, Mount Kisco, N.Y.

The patent application was filed on Feb. 28, 2012 (13/406,734). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=3&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=141&f=G&l=50&co1=AND&d=PTXT&s1=20131224.PD.&s2=%28NY.ASST.%29&OS=ISD/12/24/2013+AND+AS/NY&RS=ISD/12/24/2013+AND+AS/NY

Written by Sudarshan Harpal; edited by Jaya Anand.

SH1231JA1231-963857

© Targeted News Service, Acquiremedia 2014
Recommend :
0
React to this article
Latest news on REGENERON PHARMACEUTICALS
2d ago REGENERON PHARMACEUTICALS : Patent Issued for VEGF Antagonist Formulations for I..
2d ago REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Report on..
2d ago REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Receives EU Approval fo..
3d ago REGENERON PHARMACEUTICALS : Announces Upcoming 2014 Investor Conference Presenta..
08/13 REGENERON PHARMACEUTICALS : Robbins Arroyo LLP Is Investigating the Officers and..
08/13 REGENERON PHARMACEUTICALS : Patent Issued for Stabilized Formulations Containing..
08/12 REGENERON PHARMACEUTICALS : Financial Results, Study Results, and Proposed Merge..
08/12 REGENERON PHARMACEUTICALS : Bayer Receives EU Approval for EYLEA in Diabetic Mac..
08/11 REGENERON PHARMACEUTICALS : Assigned Patent
08/11 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives EU Approval ..
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF